Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4068472 | 0.95 | CXCR4 (0.43) | CXCR4SMN1; SMN2SIGMAR1POLBCHRM5 | |
| SCHEMBL4069687 | 0.89 | SMN1; SMN2 (0.40) | CXCR4SMN1; SMN2SIGMAR1POLBCHRM5 | |
| SCHEMBL28394391 | 0.80 | CXCR4 (0.46) | CXCR4SMN1; SMN2SIGMAR1POLBCHRM5 | |
| SCHEMBL4066936 | 0.78 | SMN1; SMN2 (0.42) | CXCR4SMN1; SMN2SIGMAR1POLBCHRM5 | |
| SCHEMBL25570473 | 0.77 | CXCR4 (0.43) | CXCR4SMN1; SMN2SIGMAR1POLBCHRM5 | |
| SCHEMBL4059396 | 0.77 | — | — | |
| SCHEMBL16589231 | 0.76 | CXCR4 (0.42) | CXCR4SMN1; SMN2SIGMAR1POLBCHRM5 | |
| SCHEMBL4063057 | 0.76 | CXCR4 (0.42) | CXCR4SMN1; SMN2SIGMAR1POLBCHRM5 | |
| SCHEMBL4062249 | 0.76 | — | — | |
| SCHEMBL4059968 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569691-B2 | Protected piperazino group-bearing organoxysilane compound and making method | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | claimed |
| US-7569691-B2 | Protected piperazino group-bearing organoxysilane compound and making method | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| EP-1714968-B1 | Protected piperazino group-bearing organoxysilane compound and making method | SHINETSU CHEMICAL CO (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-20060241294-A1 | Protected piperazino group-bearing organoxysilane compound and making method | SHIN-ETSU CHEMICAL CO., LTD. | 2006-10-26 | — | — | US | disclosed |
| EP-1714968-A1 | Protected piperazino group-bearing organoxysilane compound and making method | Shin-Etsu Chemical Co., Ltd. (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241294-A1 | Protected piperazino group-bearing organoxysilane compound and making method | PIEZO1, VCL, VIM | CXCR4 3143/4885SMN1; SMN2 1719/4885SIGMAR1 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.